Clinical Trials Browser

Observational × Biliary Tract Neoplasms × 90 days × Clear all

Biliary Tract Neoplasms

NCT01950572 2026-04-09

Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma

GastrointestinalGynecologicOther solid neoplasmThoracic

Biliary Tract Neoplasms, Lung Neoplasms, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Thymoma

NCT06973161 2026-04-08

ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors

Completed

140 enrolled

GastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT07515950 2026-04-07

REVEAL-BTC

Not yet recruiting

244 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT07319767 2026-04-06

Comparing the TDTP-RECIST With RECIST 1.1 and Other Volumetric Evaluation Methods for Assessing the Therapeutic Efficacy of Irregular Malignant Tumors

Completed

120 enrolled

BreastGastrointestinal

Biliary Tract Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06648057 2026-03-18

Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab

Recruiting

100 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT07142226 2026-03-18

Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTC

Recruiting

200 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT07151118 2026-03-18

ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer

Recruiting

100 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT07454486 2026-03-06

TRACE-BTC

Not yet recruiting

300 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Neoplasms, Cholangiocarcinoma, Klatskin Tumor, Neoplasm, Residual

NCT06793709 2026-02-27

A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy

Recruiting

60 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Neoplasms

NCT07184047 2026-02-20

TOX-FRAIL

Completed

72 enrolled

Gastrointestinal

Frailty, Biliary Tract Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Malnutrition, Sarcopenia, Sarcoglycanopathies

Clinical Trials

ARCBile

Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma

ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors

REVEAL-BTC

Comparing the TDTP-RECIST With RECIST 1.1 and Other Volumetric Evaluation Methods for Assessing the Therapeutic Efficacy of Irregular Malignant Tumors

Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab

Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTC

ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer

TRACE-BTC

A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy

TOX-FRAIL